Abstract
Objective: We present an interesting case of accidental overdose of latanoprost eye drops.
Case Report: A 71-year-old patient underwent an uncomplicated cataract surgery in his right eye. During the first postsurgical week he mistakenly used latanoprost eye drops six times daily instead of the prescribed tobramycin/dexamethasone eye drops. The patient experienced gradually decreasing visual acuity and was diagnosed with cystoid macular edema seven weeks after surgery. The cystoid macular edema resolved 4 weeks later after treatment with nepafenac 0.3% eye drops and oral acetazolamide. The cystoid macular edema recurred 2 weeks after rechallenge with latanoprost. The rechallenge-induced cystoid macular edema once again resolved after cessation of latanoprost and retreatment with nepafenac eye drops. A Naranjo assessment score of 7 was obtained, indicating a probable relationship between the patient’s symptoms and the suspect drug.
Keywords: Cystoid macular edema, uneventful phacoemulsification, latanoprost overdose, rechallenge, prostaglandin analogues, best corrected visual acuity, optical coherence tomography.
Current Drug Safety
Title:Cystoid Macular Edema Due to Accidental Latanoprost Overdose After Uncomplicated Phacoemulsification
Volume: 13 Issue: 3
Author(s): Olga E. Makri, Iasonas K. Tsekouras, Panagiotis Plotas, Foteini Tsapardoni, Athina Pallikari and Constantine D. Georgakopoulos*
Affiliation:
- Department of Ophthalmology, Medical School, University of Patras, Patras,Greece
Keywords: Cystoid macular edema, uneventful phacoemulsification, latanoprost overdose, rechallenge, prostaglandin analogues, best corrected visual acuity, optical coherence tomography.
Abstract: Objective: We present an interesting case of accidental overdose of latanoprost eye drops.
Case Report: A 71-year-old patient underwent an uncomplicated cataract surgery in his right eye. During the first postsurgical week he mistakenly used latanoprost eye drops six times daily instead of the prescribed tobramycin/dexamethasone eye drops. The patient experienced gradually decreasing visual acuity and was diagnosed with cystoid macular edema seven weeks after surgery. The cystoid macular edema resolved 4 weeks later after treatment with nepafenac 0.3% eye drops and oral acetazolamide. The cystoid macular edema recurred 2 weeks after rechallenge with latanoprost. The rechallenge-induced cystoid macular edema once again resolved after cessation of latanoprost and retreatment with nepafenac eye drops. A Naranjo assessment score of 7 was obtained, indicating a probable relationship between the patient’s symptoms and the suspect drug.
Export Options
About this article
Cite this article as:
Makri E. Olga , Tsekouras K. Iasonas , Plotas Panagiotis , Tsapardoni Foteini , Pallikari Athina and Georgakopoulos D. Constantine *, Cystoid Macular Edema Due to Accidental Latanoprost Overdose After Uncomplicated Phacoemulsification, Current Drug Safety 2018; 13 (3) . https://dx.doi.org/10.2174/1574886313666180619163845
DOI https://dx.doi.org/10.2174/1574886313666180619163845 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer as the Main Aging Factor for Humans: The Fundamental Role of 5-Methoxy-Tryptamine in Reversal of Cancer-Induced Aging Processes in Metabolic and Immune Reactions by Non-melatonin Pineal Hormones
Current Aging Science Genetic Insights into Sepsis: What have we Learned and How will it Help?
Current Pharmaceutical Design Proteasome Inhibitors Therapeutic Strategies for Cancer
Recent Patents on Anti-Cancer Drug Discovery Different Concepts of Drug Delivery in Disease Entities
Mini-Reviews in Medicinal Chemistry The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Cerebral Hypoperfusion in Hereditary Coproporphyria (HCP): A Single Photon Emission Computed Tomography (SPECT) Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeted Cancer Immunotherapy Using Ligands of the Tumor Necrosis Factor Super-Family
Current Drug Targets Necrosis Avidity of Organic Compounds: A Natural Phenomenon with Exploitable Theragnostic Potentials
Current Medicinal Chemistry Electrochemical Determination of Non-Steroidal Anti-Inflammatory Drugs
Current Analytical Chemistry Harnessing Telomerase in Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Nanoformulations Enabled Possible Solutions for the Management of Psoriasis
Current Cosmetic Science Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Influence of Sex Hormones on Pulmonary Vascular Reactivity: Possible Vasodilator Therapies for the Treatment of Pulmonary Hypertension
Current Vascular Pharmacology 11C-verapamil to Assess P-gp Function in Human Brain During Aging,Depression and Neurodegenerative Disease
Current Topics in Medicinal Chemistry Characterisation of Bacillus subtilis Transcriptional Regulators Involved in Metabolic Processes
Current Protein & Peptide Science Schistosoma mansoni Antigens as Modulators of the Allergic Inflammatory Response in Asthma
Endocrine, Metabolic & Immune Disorders - Drug Targets Critical Role of Hypoxia Sensor - HIF-1α in VEGF Gene Activation. Implications for Angiogenesis and Tissue Injury Healing
Current Medicinal Chemistry Ruthenium as an Effective Nitric Oxide Scavenger
Current Topics in Medicinal Chemistry The Influence of TNF-α, IL-6, TGF-β1, IFN-γ, IL-10 Polymorphisms on Predisposition to Diabetes Mellitus among Jordanian Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Gastroduodenal Disorders in Patients with CVID Undergoing Immunoglobulin Therapy
Current Pharmaceutical Biotechnology